XML 21 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended 154 Months Ended
Mar. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2024
Cash flows from operating activities:        
Net loss   $ (118,961) $ (276,056)  
Adjustments to reconcile net loss to net cash used in operating activities:        
Non-cash royalty revenue related to the sales of future royalties   (64,267) (68,921) $ (536,433)
Non-cash interest expense on liabilities related to sales of future royalties   28,112 25,334 326,630
Stock-based compensation   21,612 33,388  
Depreciation and amortization   4,391 7,815  
Impairment of right-of-use assets and property, plant and equipment   8,329 35,328  
Impairment of goodwill $ 76,500 0 76,501  
Gain on sale of the Huntsville manufacturing facility   (40,390) 0  
(Gain) loss on sale or disposal of property, plant and equipment, net   0 1,300  
Provision for net realizable value of inventory   949 2,402  
Foreign currency translation adjustment   0 5,099  
Amortization of premiums (discounts), net   (9,245) (14,856)  
Changes in operating assets and liabilities:        
Accounts receivable   (3,045) 4,776  
Inventory   497 699  
Operating leases, net   (12,905) (8,850)  
Other assets   (4,187) 3,583  
Accounts payable   2,668 (2,884)  
Accrued expenses   10,733 (17,264)  
Net cash used in operating activities   (175,709) (192,606)  
Cash flows from investing activities:        
Purchases of investments   (261,709) (511,699)  
Maturities of investments   340,361 650,883  
Proceeds from sale of the Huntsville manufacturing facility, net   65,386 0  
Sales of investments   0 0  
Purchases of property, plant and equipment   (1,468) (865)  
Sales of property, plant and equipment   0 1,245  
Net cash provided by investing activities   142,570 139,564  
Cash flows from financing activities:        
Proceeds from shares issued under equity compensation plans   118 30  
Proceeds from issuance of pre-funded warrant   30,000 0  
Proceeds from sale of future royalties   15,000 0  
Repurchase of common stock from Bristol-Myers Squibb   (3,000) 0  
Net cash provided by financing activities   42,118 30  
Effect of foreign exchange rates on cash and cash equivalents   (4) 62  
Net increase (decrease) in cash and cash equivalents   8,975 (52,950)  
Cash and cash equivalents at beginning of year $ 88,227 35,277 88,227  
Cash and cash equivalents at end of year   44,252 35,277 $ 44,252
Non-cash investing and financing activities:        
Fair value of equity method investment in Gannet BioChem received in exchange for sale of Huntsville manufacturing facility   12,218 0  
Transaction costs and net working capital adjustment for sale of Huntsville manufacturing facility included in accounts payable and accrued expenses   697 0  
Supplemental disclosure of cash flow information:        
Cash paid for income taxes   $ 76 $ 2,656